Change in endothelial function state under the influence of antihypertensive therapy in patients with arterial hypertension and high cardiovascular risk.

T. S. Turlyun

doi:10.26641/2307-0404.2014.1.24487

Авторы

T. S. Turlyun

DOI:

https://doi.org/10.26641/2307-0404.2014.1.24487

Ключевые слова:

arterial hypertension, diabetes mellitus type 2, endothelial dysfunction, endothelin-1, losartan potassium

Аннотация

The article analyzes the indicators characterizing endothelial function in patients of distinguished groups at the initial stage of the study (visit 1) and during the treatment (visit 2). At baseline levels of endothelin-1 in the blood of patients of all groups did not differ significantly between the groups distinguished. After treatment, the dynamics of the indicator in all groups was positive and statistically significant (p<0,05): the level of ET-1 in the group with HD decreased by 7,7%, more pronounced changes were observed in hypertensive patients with type 2 diabetes - indicator decreased by 21,7% (p<0,05), testifying to reducing of endothelin-1 formation and its entering to the blood.When comparing control and treatment groups (0,37±0,06 fmol/ml) a twofold excess of endothelin-1 in hypertensive groups (p<0,01) and in patients with hypertension and diabetes mellitus type 2 (p<0,01) was observed. After the treatment with losartan potassium and hydrochlorothiazide, a statistically significant reduction of ET-1 in the group without hypertension comorbidity (p<0,004) and in the group of hypertensive type 2 diabetic (p<0,004) was noted. Dynamics of ET-1 decrease in the group with type 2 diabetes, but statistically unreliable (p<0,233) was noted. Under the influence of losartan potassium and hydrochlorothiazide average albuminuria level decreased in groups of patients with hypertension and hypertension with type 2 diabetes (p<0,05). In patients with type 2 diabetes who were not taking antihypertensive drugs, the rate did not change (p>0,60).

Биография автора

T. S. Turlyun

SE «Dnepropetrovsk medical academy of Health Ministry of Ukraine»
Department of Faculty Therapy and Endocrinology
Vorontsov av., 29, Dnepropetrovsk, 49023, Ukraine

Библиографические ссылки

Абрагамович О.О. Механізми розвитку дис¬функ¬ції ендотелію та її роль у патогенезі ішемічної хво¬роби серця / О.О. Абрагамович, А.Ф. Файник, О.В. Не¬чай // Укр. кардіол. журнал. – 2007. - № 4. – С. 81-87.

Ватутин Н.Т. Эндотелины и сердечно-сосу¬дистая патология / Н.Т. Ватутин, Н.В. Калинкина, А.Л. Демидова // Укр. кардіол. журнал. – 2006. – № 1. – С. 101-106.

Иванов Д.Д. Микроальбуминурия: взгляд неф¬ро¬лога / Д.Д. Иванов // Здоровье Украины. — 2008. — Т. 21, № 1. — С. 18-19.

Мельникова О.Г. Британское проспективное исследование сахарного диабета (UKPDS) – резуль¬таты 30-летнего наблюдения больных СД 2 типа / О.Г. Ме¬ль¬никова // Сахарный диабет. – 2008. – № 4. – С. 90-91.

Поливода С.Н. Поражение органов-мишеней при гипертонической болезни: практ. руководство / С.Н. Поливода, Ю.М. Колесник, А.А. Черепок. – К.: Чет¬верта хвиля, 2005. – 800 с.

Тихонова С.А. XVII конгресс Европейского об¬щества гипертензии и кардиологов: новые реко¬мен¬дации по артериальной гипертензии / С.А. Тихонова // Здоровье Украины.- 2007. – Т. 12, № 1. – С. 10-13.

Ющук Е.Н. Эндотелиальная дисфункция при заболеваниях сердечно-сосудистой системы и методы ее коррекции / Е.Н. Ющук, Ю.А. Васюк, А.Б. Хад¬зегова // Клинич. фармакология и терапия. – 2005. – Т. 14, № 3. – С. 85-88.

American Diabetes Association. Standards of Medical Care in Diabetes // Diabetes Care. – 2011. – Vol. 34. – P. 11-61.

Initial monotherapy and combination therapy and hypertension control the first year / B.M. Egan, D. Ban¬dyopadhyay, S.R. Shaftman [et al.] // Hypertension. – 2012. – Vol. 59. – P. 1124-1131.

Gupta A.K. Compliance, safety, and effectiveness offixed_dose combinations of antihypertensive agents: a metaanalysis / A.K. Gupta, S. Arshad, N.R. Poulter // Hy¬pertension. – 2010. – Vol. 55. – P. 399-407.

Risk prediction is improved by adding markers of subclinical organ damage to SCORE / T. Sehestedt, J.J eppesen, T.W. Hansen [et al.] // Eur. Heart J. – 2010. –Vol. 31. – P. 883-891.

Abragamovich OO, Faynik AF, Nechay OV. [Mechanisms of development of epithelial dysfunction and their role in pathogenesis of ischemic heart disease]. Ukr. kardiologichnyi zhurnal. 2007;4:81-87. Ukrainian.

Vatutin NT, Kalinkina NV, Demidova AL. [Endothelins and cardio-vascular pathology]. Ukr. kardio¬logichnyi zhurnal. 2006;1:101-6. Russian.

Ivanov DD. [Microalbuminuria: view of nephro¬logist]. Zdorov'e Ukrainy. 2008;21(1):18-19. Russian.

Mel'nikova OG. [Britain prospective investigation of diabetes melitus]. Sakharnyy diabet. 2008;4:90-91. Russian.

Polivoda SN, Kolesnik YuM, Cherepok AA. [Lesion of target organs in hypertension: Practical guidance]. Chetverta khvilya. 2005:800. Russian.

Tikhonova SA. [XVII Congress of European society of hypertension and cardiology: new recom¬mendations on arterial hypertension]. Zdorov'e Ukrainy. 2007;12(1):10-13. Russian.

Yushchuk EN, Vasyuk YuA, Khadzegova AB. [Endothelial dysfunction in cardio-vascular diseases and methods of its correction]. Klinichna farmakologya i terapya. 2005;14(3):85-88. Russian.

American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2011;34:11-61.

Egan BM, Bandyopadhyay D, Shaftman SR. Ini¬tial monotherapy and combination therapy and hyper¬ten¬sion control the first year. Hypertension. 2012;59:1124-31.

Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness offixed_dose combinations of antihypertensive agents: a metaanalysis. Hypertension. 2010;55:399-407.

Sehestedt T, Jeppesen J, Hansen TW. Risk pre¬diction is improved by adding markers of subclinical organ damage to SCORE. Eur. Heart J. 2010;31:883-91.